Effect of a 5HT3‐antagonist (ondansetron) on rectal sensitivity and compliance in health and the irritable bowel syndrome
- 1 October 1993
- journal article
- clinical trial
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 7 (5), 543-551
- https://doi.org/10.1111/j.1365-2036.1993.tb00131.x
Abstract
SUMMARY: In some patients with the irritable bowel syndrome, rectal urgency and discomfort are major clinical problems and, under experimental conditions, these symptoms are perceived at lesser volumes of rectal distension than they are in asymptomatic controls. Further, a 5‐hydroxytryptamine type‐3 receptor antagonist increased the threshold for rectal discomfort in irritable bowel syndrome. Our aims were, (a) to measure rectal sensation during isobaric distensions of the rectum, and (b) to test the effect of another selective 5HT3antagonist, ondansetron 0.15 mg/kg, on rectal sensitivity, colonic tone, rectal tone and manometric responses. Ten healthy volunteers and five patients with diarrhoea‐predominant irritable bowel syndrome were studied. A multilumen barostatmanometric assembly was placed in the descending colon, and a second barostat balloon was positioned in the rectum. Tone in the wall of the colon and rectum was measured by the barostat balloon volume during a constant pressure clamp, while intraluminal pressures were recorded by manometry; perceived sensations were also recorded before and after the intravenous administration of ondansetron or placebo in blinded fashion. Rectal resistance to stretch was greater and rectal urgency was induced by lower distending pressures in irritable bowel syndrome, however, basal tone in the rectum was similar in health and irritable bowel syndrome. Ondansetron did not change rectal sensitivity (first sensation or urgency) or tone. Rectal distension did not alter tone in the descending colon or colonic manometry; ondansetron did not influence any index of colonic function. We conclude that in diarrhoea‐predominant irritable bowel syndrome there is reduced rectal compliance and the rectum is abnormally sensitive to a pressure stimulus, but this is not altered by 5HT3‐blockade with ondansetron at the dose used.Keywords
This publication has 20 references indexed in Scilit:
- Reduction of rectal sensitivity and post‐prandial motility by granisetron, a 5 HT3‐receptor antagonist, in patients with irritable bowel syndromeAlimentary Pharmacology & Therapeutics, 1993
- Colonic Tone and Motility in Patients With Irritable Bowel SyndromeMayo Clinic Proceedings, 1992
- Control of muscle tone in the human colon.Gut, 1992
- The effects of granisetron, ICS 205–930 and ondansetron on the visceral pain reflex induced by duodenal distensionBritish Journal of Pharmacology, 1990
- Colonic transit in man is slowed by ondansetron (GR38032F), a selective 5‐hydroxytryptamine receptor (type 3) antagonistAlimentary Pharmacology & Therapeutics, 1990
- Anorectal manometry in irritable bowel syndrome: differences between diarrhoea and constipation predominant subjects.Gut, 1990
- Diagnostic value of the Manning criteria in irritable bowel syndrome.Gut, 1990
- 5-Hydroxytryptamine: New Receptors and Novel Drugs for Gastrointestinal Motor DisordersScandinavian Journal of Gastroenterology, 1990
- Modulation of human upper gastrointestinal motility by rectal distension.Gut, 1987
- PREVENTION OF EMESIS IN PATIENTS RECEIVING CYTOTOXIC DRUGS BY GR38032F, A SELECTIVE 5-HT3 RECEPTOR ANTAGONISTThe Lancet, 1987